How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,046 results for

Procainamide

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Fingolimod (Gilenya): new contraindications in relation to cardiac risk

requiring treatment with class Ia (eg, quinidine, procainamide, disopyramide) and class III (potassium‐channel blockers—eg, amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmic drugs second‐degree Mobitz type II atrioventricular (AV) block or third‐degree AV block, or sick‐sinus syndrome, if they do not have a pacemaker pre-treatment QT intervals ≥500 milliseconds report all suspected adverse drug reactions with fingolimod on a is authorised to treat relapsing-remitting multiple sclerosis

2017 MHRA Drug Safety Update

142. Intravenous Flecainide for Emergency Department Management of Acute Atrial Fibrillation. (PubMed)

AF were selected for meta-analysis.Four hundred and three studies were screened, of which 11 RCTs were eligible for meta-analysis. Flecainide had high efficacy for cardioversion within 2 h (number needed to treat [NNT] = 1.8). Efficacy was superior to propafenone, amiodarone, procainamide, ibutilide, and sotalol (NNT = 4.3). There was no statistically significant difference in pro-dysrhythmia compared to these anti-dysrhythmics or placebo.Intravenous flecainide cardioversion could be a safe

2017 Journal of Emergency Medicine

143. Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on ART

a fully active alternative cART regimen based on previous resistance testing and/or treatment history. Use of the following medications that carry risk of torsade des pointes: amiodarone, arsenic trioxide, astemizole, bepridil, chloroquine, chlorpromazine, cisapride, clarithromycin, disopyramide, dofetilide, domperidone, droperidol, erythromycin, halofantrine, haloperidol, ibutilide, levomethadyl, mesoridazine, methadone, pentamidine, pimozide, probucol, procainamide, quinidine, sotalol, sparfloxacin

2017 Clinical Trials

144. Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

antibody therapies Pregnant or breastfeeding Evidence of corrected QT (QTc) prolongation on pretreatment electrocardiography (ECG) (greater than 440 ms in males or greater than 460 ms in females) Lab values that in the opinion of the primary surgeon would prevent surgical resection Patients receiving class IA (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents Contacts and Locations Go to Information from the National Library of Medicine To learn more about

2017 Clinical Trials

145. Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study

, procainamide, disopyramide, propafenone, azole antifungals, fluoroquinolones, macrolide antibiotics, HIV antiretrovirals, chemotherapy, beta-2 agonists, tricyclic antidepressants, selective serotonin reuptake inhibitors Prior surgeries for achalasia < 2 months since last endoscopic botulinum toxin injection into LES or endoscopic dilation Stage 4 Chronic kidney disease (severe renal impairment with GFR 15-29 ml/min), Stage 5 Chronic Kidney disease (GFR < 15 ml/min or on dialysis) Childs Pugh B (moderate

2017 Clinical Trials

146. Dysregulation of miR-155-5p and miR-200-3p and the Anti-Non-Bilayer Phospholipid Arrangement Antibodies Favor the Development of Lupus in Three Novel Murine Lupus Models (PubMed)

Dysregulation of miR-155-5p and miR-200-3p and the Anti-Non-Bilayer Phospholipid Arrangement Antibodies Favor the Development of Lupus in Three Novel Murine Lupus Models Systemic lupus erythematosus (SLE) is characterized by deregulated activation of T and B cells, autoantibody production, and consequent formation of immune complexes. Liposomes with nonbilayer phospholipid arrangements (NPA), induced by chlorpromazine, procainamide, or manganese, provoke a disease resembling human lupus when

Full Text available with Trip Pro

2017 Journal of immunology research

147. Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer

3 months before screening visit, > class 2 New York Heart Association heart failure, > grade 2 Canadian cardiovascular society angina pectoris, or receiving quinidine, procainamide, disopyramide, amiodarone, dronedarone, arsenic, dofetilide, or sotalol methadone. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer

2017 Clinical Trials

148. Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix

of Firmagon® patients who receive concomitant medications that might prolong the QT interval, in particular class I A (such as quinidine, procainamide, disopyramide,) or class III antiarrhythmics (such as amiodarone, sotalol, dofetilide, ibutilide) patients with history of or risk factors for Torsades de Pointes patients who take either methadone or moxifloxacin or antipsychotic patients with alteration in electrolyte blood levels (such as sodium, potassium, calcium and magnesium) patients with severe

2017 Clinical Trials

149. Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients

of their components is contra-indicated, including but not limited to drug allergy. Use of any drug within 30 days prior to randomisation known to prolong QTc interval (including, but not limited to, amiodarone, amitriptyline, bepridil, chloroquine, chlorpromazine, cisapride, clarithromycin, disopyramide dofetilide, domperidone, droperidol, erythromycin, halofantrine, haloperidol, ibutilide, levomethadyl, mesoridazine, methadone, pentamidine, pimozide, procainamide, quinacrine, quinidine, sotalol, sparfloxacin

2017 Clinical Trials

150. Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid

to prolong the QTc interval (erythromycin, clarithromycin, astemizole, type Ia [quinidine, procainamide, disopyramide] and III [amiodarone, sotalol] anti-arrhythmics, carbamazepine, sulfonylureas, and meperidine), within 30 days before the first dose of study drug or during the study drug treatment period. Use of any adrenergic/serotonergic agonists, such as pseudoephedrine and phenylpropanolamine (frequently found in cold and cough remedies), within 7 days before the first dose of study drug or during

2017 Clinical Trials

151. A Phase 2A Evaluation of the Safety, Tolerability, Pharmacokinetics, Efficacy of Clofazimine (CFZ) in Cryptosporidiosis

, Bepridil, Chloroquine, Chlorpromazine, Cisapride, Clarithromycin, Cyclobenzaprine, Darunavir, Delamanid, Disopyramide Dofetilide, Domperidone, Droperidol, Erythromycin, Fosamprenavir, Halofantrine, Haloperidol, Ibutilide, Indinavir, Levomethadyl, Lopinavir, Mesoridazine, Methadone, Nelfinavir, Pentamidine, Pimozide, Procainamide, Quinidine, Ritonavir, Simiprinivir, Sotalol, Sparfloxacin, Thioridazine, or Tiprinivir Pregnant and lactating women (screening pregnancy test for females and pregnancy test

2017 Clinical Trials

152. The Role of Electrophysiology Testing in Survivors of Unexplained Cardiac Arrest

for eligibility information Ages Eligible for Study: Child, Adult, Older Adult Sexes Eligible for Study: All Accepts Healthy Volunteers: No Sampling Method: Non-Probability Sample Study Population Survivors of unexplained sudden cardiac death for whom an underlying etiology remains unclear following a standard diagnostic workup, including 12-lead surface ECG, coronary artery assessment, echocardiography, cardiac MRI with late gadolinium enhancement, procainamide challenge, and exercise treadmill testing

2017 Clinical Trials

153. Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix)

foresees potential risks for serotonin syndrome when combined with linezolid. Concomitant use of any drug known to prolong QTc interval (including, but not limited to, amiodarone, bepridil, chloroquine, chlorpromazine, cisapride, cyclobenzaprine, clarithromycin, disopyramide, dofetilide, domperidone, droperidol, erythromycin, fluoroquinolones, halofantrine, haloperidol, ibutilide, levomethadyl, mesoridazine, methadone, pentamidine, pimozide, procainamide, quinidine, sotalol, sparfloxacin, thioridazine

2017 Clinical Trials

154. A Study to Assess the Safety and Tolerability Profile of TR399 in Healthy Volunteers and Erectile Dysfunction Patients

disorder that is not suitable for sexual activities. Use of antiarrhythmic agents class IA (such as quinidine, or procainamide) and class III (such as amiodarone or sotalol) within 2 weeks prior to the screening visit With priapism, such as sickle cell anemia, multiple myeloma or leukemia Phase IIa Known or suspected allergy, hypersensitivity, or intolerance to any ingredients of study product Participated in another clinical trial and received any investigational drug within four weeks prior (...) cardiovascular disorder that is not suitable for sexual activities. Use of antiarrhythmic agents class IA (such as quinidine, or procainamide) and class III (such as amiodarone or sotalol), within 2 weeks prior to the screening visit With priapism, such as sickle cell anemia, multiple myeloma or leukemia Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided

2017 Clinical Trials

155. Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer

screening visit; > class 2 New York Heart Association heart failure; or > class 2 angina pectoris; or receiving quinidine, procainamide, disopyramide, amiodarone, dronedarone, arsenic, dofetilide, sotalol, or methadone. Please also see prohibited medication/therapy (Section 5.4.10.1) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor

2017 Clinical Trials

156. Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer

jeopardize the safety of the patient or the validity of the study results. Have a baseline corrected QT interval > 450 ms or patients with known long QT syndrome, torsade de pointes, symptomatic ventricular tachycardia, unstable cardiac syndrome in the past 3 months before screening visit, > class 2 NYHA (The New York Heart Association Functional Classification heart failure), > grade 2 CCS (the Canadian Cardiovascular Society Guidelines) angina pectoris, or receiving quinidine, procainamide

2017 Clinical Trials

157. Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate

IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. Magnesium, potassium and calcium lower than the lower limit of normal range. Life expectancy < 12 weeks Karnofsky performance status < 70% Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its

2017 Clinical Trials

158. LITFL Review 241

] Scott Weingart answers a post peer review question: [SR] The Bottom Line looks at a paper on high flow nasal oxygen in the ED, . [SL] The Best of Critical Care If you missed it last week: Is there any benefit in ? Here is the Bottom Line. [JS] The Best of Resuscitation Amiodarone is the best anti-arrhythmic. Or is it? Rory Spiegel discusses the data on amiodarone vs procainamide in “ ”. [SO] The Best of Ultrasound Matt and Mike discuss the use of ultrasound in trauma- this time focused on [SO

2016 Life in the Fast Lane Blog

159. Research and Reviews in the Fastlane 144

the world tell us what they think is worth reading from the published literature. This edition contains 6 recommended reads . The R&R Editorial Team includes Jeremy Fried, Nudrat Rashid, Soren Rudolph, Justin Morgenstern, Anand Swaminathan and, of course, Chris Nickson. Find more R&R in the Fastlane reviews in the , read more or check out the This Edition’s R&R Hall of Famer Cardiology Ortiz M, et al. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment (...) of tolerated wide QRS tachycardia: the PROCAMIO study. European heart journal. 2016. PMID: The evidence for amiodarone has always been on the weak side. This is a good paper that should be practice changing for some people. It is a multicenter, randomized trial comparing amiodarone (5mg/kg over 20 minutes) to procainamide (10mg/kg over 20 min) in 74 adult patients with hemodynamically stable ventricular tachycardia. Procainamide was better. The primary outcome of cardiac adverse events (mostly hypotension

2016 Life in the Fast Lane Blog

160. J K Aronson – The Hitchhiker’s Guide to Clinical Pharmacology Part 2

-glucuronide Procainamide Acecainide Spironolactone Canrenone Sulfasalazine Mesalazine Terfenadine Fexofenadine Other drugs that were discovered independently and that are metabolized to active compounds include codeine, diamorphine, and tramadol (all metabolized to morphine), tamoxifen (metabolized to 4-hydroxytamoxifen), and aspirin (metabolized to salicylate). In some cases active metabolites cause adverse effects; these include the metabolites of lidocaine (the glycine xylidides) and pethidine

2016 CEBM blog

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>